Eli Lilly Canada Inc. (Lilly) is requesting reimbursement for EMGALITY® (galcanezumab) for the prevention of migraine in adults who have at least four migraine days per month and have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Emgality is indicated for the prevention of migraine in adults who have at least four migraine days per month.
The requested reimbursement criteria are provided by the applicant and do not
the views of CADTH. Reimbursement criteria from CADTH will be documented in the final
recommendation, if applicable.